TriangleNCT00577798 · OUTCOME
Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen.
What was measured
A reduction of 10% in left ventricular ejection fraction (LVEF) between the two cMRI studies was considered a subclinical functional event. New or progressive myocardial delayed enhancement within ≥1 segment was deemed as a subclinical structural event. Global left ventricle (LV) radial, circumferential, and longitudinal strain data for each patient were compared between cMRI-1 and cMRI-2. The study had a fixed endpoint (3 months post-treatment)
Analysis population: Ejection fraction (EF) and delayed gadolinium enhancement from cMRI at baseline and 3 months post-treatment will be determined and tested.
Groups in this outcome
Contrast-enhanced Magnetic Resonance Imaging
Doxorubicin hydrochloride: Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lymphoma and Hogdkin's lymphoma Contrast-enhanced magnetic resonance imaging: Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).
| Group | Source count |
|---|---|
| Contrast-enhanced Magnetic Resonance Imaging | 10 |
Reported measurements
Source class 1
EF determined from cMRI at baseline and 3 months post-treatment.
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Contrast-enhanced Magnetic Resonance Imaging | 5 | Not reported | Not reported | Not reported | Not reported |
Delayed gadolinium enhancement from cMRI at baseline and 3 months post-treatment.
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Contrast-enhanced Magnetic Resonance Imaging | 5 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 5
- title
- EF determined from cMRI at baseline and 3 months post-treatment.
- measurements
- group Id
- OG000
- value
- 5
- title
- Delayed gadolinium enhancement from cMRI at baseline and 3 months post-treatment.
- denoms
- counts
- group Id
- OG000
- value
- 10
- units
- Participants
- description
- A reduction of 10% in left ventricular ejection fraction (LVEF) between the two cMRI studies was considered a subclinical functional event. New or progressive myocardial delayed enhancement within ≥1 segment was deemed as a subclinical structural event. Global left ventricle (LV) radial, circumferential, and longitudinal strain data for each patient were compared between cMRI-1 and cMRI-2. The study had a fixed endpoint (3 months post-treatment)
- groups
- description
- Doxorubicin hydrochloride: Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lymphoma and Hogdkin's lymphoma Contrast-enhanced magnetic resonance imaging: Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).
- id
- OG000
- title
- Contrast-enhanced Magnetic Resonance Imaging
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Ejection fraction (EF) and delayed gadolinium enhancement from cMRI at baseline and 3 months post-treatment will be determined and tested.
- reporting Status
- POSTED
- time Frame
- cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen.
- title
- Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice